TY  - JOUR
T1  - Cytotoxicity of Galantamine Peptide Esters Against Hela Cell Lin
A1  - Dobrina Tsvetkova
A1  - Lyubomir Vezenkov
A1  - Tchavdar Ivanov
A1  - Dancho Danalev
A1  - Ivanka Kostadinova
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2023
VL  - 14
IS  - 3
DO  - 10.51847/E1l0KDSnG1
SP  - 131
EP  - 138
N2  - In this study, the cytotoxic potential of newly synthesized peptide esters of Galantamine, namely GAL-VAL and GAL-LEU, was investigated against the human cervical adenocarcinoma cell line (HeLa) across a range of concentrations spanning from 1.875µM to 30µM. Notably, GAL-LEU demonstrated significant efficacy in suppressing HeLa cells, particularly at a concentration of 30 µM, where it elicited an impressive 86.81% reduction in cell viability. This effect was corroborated by a corresponding index of cell viability of 13.19%. Further analysis revealed that GAL-LEU possessed a substantially lower IC50 value of 23.63 µM compared to GAL-VAL, which exhibited an IC50 value of 31.95µM. These findings highlight the pronounced cytotoxic effects of both esters on the HeLa cell line, with GAL-LEU exhibiting superior antiproliferative potency. The results of this investigation suggest the potential utility of GAL-VAL and GAL-LEU as promising candidates warranting further exploration in cancer therapeutics, particularly in the context of addressing cervical adenocarcinoma.
UR  - https://pharmacophorejournal.com/article/cytotoxicity-of-galantamine-peptide-esters-against-hela-cell-lin-l3vjyimhsdlbqim
ER  -